1. Home
  2. MKZR vs BIAF Comparison

MKZR vs BIAF Comparison

Compare MKZR & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MacKenzie Realty Capital Inc.

MKZR

MacKenzie Realty Capital Inc.

HOLD

Current Price

$1.29

Market Cap

4.6M

Sector

N/A

ML Signal

HOLD

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

HOLD

Current Price

$0.63

Market Cap

4.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MKZR
BIAF
Founded
2012
2014
Country
United States
United States
Employees
N/A
57
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6M
4.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MKZR
BIAF
Price
$1.29
$0.63
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
16.8K
288.1K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$20.95
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$0.23
52 Week High
$6.99
$13.50

Technical Indicators

Market Signals
Indicator
MKZR
BIAF
Relative Strength Index (RSI) 25.87 24.92
Support Level N/A $0.61
Resistance Level $1.84 $0.87
Average True Range (ATR) 0.11 0.05
MACD -0.01 0.03
Stochastic Oscillator 37.84 13.70

Price Performance

Historical Comparison
MKZR
BIAF

About MKZR MacKenzie Realty Capital Inc.

Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate. It is a real estate investment manager who utilizes an approach to real estate securities, often seeing opportunities that others overlook. Based in Orinda, California, MacKenzie Capital Management has specialized in discounted real estate securities and asset management.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Share on Social Networks: